Most frequent questions and answers
Cancertrack™ has been validated clinically on several hundred samples and the process validation meets and exceeds the claimed sensitivity and specificity. Our laboratory is accredited by ISO 9001:2015, ISO 15189: 2012, ISO 27001:2013 and CLIA besides its compliance to “The College of American Pathologists” guidelines. All Cancertrack™ reports are reviewed by our experienced and qualified Molecular Tumor Board, comprising of experts in the field. Our counsellors and experts are available for ongoing support.
Cancertrack™ should ideally be performed at every important milestone in the fight against cancer and especially when the tumor has disappeared from the conventional imaging/patient is under follow-up for recurrence monitoring.
While Cancertrack™ is extremely robust and multi-dimensional, like every molecular diagnostic technique, constraints naturally arising due to biological function in an individual patient may impact performance. However, such events are usually averaged out in sequential testing.